Torrent Pharmaceuticals Limited
Records under this name other than the patents Torrent Pharmaceuticals Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.
Back to Torrent Pharmaceuticals Limited
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,822,484 | Novel Fused Thiazolo and Oxazolo Pyrimidinones Lapsed on the fee record Ended Sep 2, 2026 · High confidence | Lapsed on the fee record | Ended Sep 2, 2026 | High confidence |
| US 9,963,463 | Urea-substituted indanes as P38 map kinase inhibitors Lapsed on the fee record Ended May 8, 2026 · USPTO record | Lapsed on the fee record | Ended May 8, 2026 | USPTO record |
| US 9,908,898 | Fused imidazobenzothiazole compounds Lapsed on the fee record Ended Mar 6, 2026 · USPTO record | Lapsed on the fee record | Ended Mar 6, 2026 | USPTO record |
| US 8,604,222 | Nebivolol and Its Pharmaceutically Acceptable Salts, Process for Preparation and Pharmaceutical Compositions of Nebivolol Formerly held Lapsed on the fee record Ended Dec 10, 2025 · High confidence | Lapsed on the fee record | Ended Dec 10, 2025 | High confidence |
| US 8,541,430 | Novel Fused Thiazolo and Oxazolo Pyrimidinones Lapsed on the fee record Ended Sep 24, 2025 · High confidence | Lapsed on the fee record | Ended Sep 24, 2025 | High confidence |
| US 8,633,241 | Nebivolol and its Pharmaceutically Acceptable Salts, Process for Preparation and Pharmaceutical Compositions of Nebivolol Formerly held Term ended Term ended Aug 1, 2025 · High confidence | Term ended | Term ended Aug 1, 2025 | High confidence |
| US 9,610,247 | Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease Formerly held Lapsed on the fee record Ended Apr 4, 2025 · USPTO record | Lapsed on the fee record | Ended Apr 4, 2025 | USPTO record |
| US 8,378,118 | Pyrazole-based thyroid receptor compounds Lapsed on the fee record Ended Feb 19, 2025 · USPTO record | Lapsed on the fee record | Ended Feb 19, 2025 | USPTO record |
| US 10,772,879 | Pharmaceutical formulations Lapsed on the fee record Ended Sep 15, 2024 · USPTO record | Lapsed on the fee record | Ended Sep 15, 2024 | USPTO record |
| US 10,717,727 | Pyridinium compounds Lapsed on the fee record Ended Jul 21, 2024 · USPTO record | Lapsed on the fee record | Ended Jul 21, 2024 | USPTO record |